ArticleMolecular neurobiology2026
Pharmacogenetic Impact of CYP2C19 Variants on Diazepam Treatment Outcomes in Alcohol Withdrawal Syndrome.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Diazepam (DZP) is widely accepted as an effective pharmaceutical intervention for treating Alcohol Withdrawal Syndrome (AWS), and its efficacy and metabolic profile are influenced by genetic variations in the CYP2C19 gene. The objective of the present study was to investigate the impact of the CYP2C19*2 and CYP2C19*17 phenotypes on DZP metabolism. Whole blood samples were collected from 114 patients with AWS following a 10-day course of oral DZP therapy. Genotyping was performed using PCR-RFLP. Plasma concentrations of DZP and nordiazepam (NDZP) were determined using HPLC-UV. The CYP2C19*17 TT genotype (1.597 ± 0.589) showed a significantly higher metabolic ratio (MR) compared to CC (1.159 ± 0.423) and CT (1.374 ± 0.368) genotypes (p = 0.015). Withdrawal severity after treatment was significantly lower in TT carriers than in CC and CT genotypes (p = 0.043). Pharmacokinetic and clinical parameters varied across CYP2C19 diplotypes, with ultrarapid (*17/*17) and rapid (*1/*17) metabolisers demonstrating higher MR and lower withdrawal severity compared to extensive metabolisers (*1/*1). The CYP2C19*2 haplotype was associated with higher dose-normalised DZP concentrations, whereas CYP2C19*17 was associated with a higher metabolic ratio. This study is the first to quantify plasma DZP and NDZP levels after 10-day oral administration and link them to CYP2C19*2 and CYP2C19*17 genotypes, haplotypes and diplotypes. The metabolic ratio (NDZP/DZP) emerged as a more integrative indicator of CYP2C19 activity than absolute levels, highlighting the complex genotype-phenotype relationship in DZP metabolism. Notably, the CYP2C19*17 gain-of-function allele significantly was associated with increased metabolic efficiency and improved clinical outcomes in AWS.
Indexed as
Identifiers
42891844What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.